

FINANCIAL STATEMENTS

DANANG PHARMACEUTICAL - MEDICAL EQUIPMENT JOINT STOCK COMPANY

For the fiscal year ended as at 31/12/2025
(audited)



CONTENTS

	Page
Report of the Board of Management	02 - 03
Independent Auditors' Report	04 - 05
Audited Financial Statements	06 - 43
Statement of Financial Position	06 - 07
Statement of Income	08
Statement of Cash flows	09 - 10
Notes to the Financial Statements	11 - 43

REPORT OF THE BOARD OF MANAGEMENT

The Board of Management of Danang Pharmaceutical - Medical Equipment Joint Stock Company ("the Company") presents its report and the Company's Financial Statements for the fiscal year ended as at 31/12/2025.

THE COMPANY

Danang Pharmaceutical - Medical Equipment Joint Stock Company was established and operates under the Business Registration Certificate of Joint Stock Company No. 0400101404 issued for the first time on March 22, 2005, amended for the 18th time on July 11, 2025 by Da Nang City Department of Planning and Investment (currently Da Nang City Department of Finance).

The Company's head office is located at: No. 02, Phan Dinh Phung Street, Hai Chau Ward, Da Nang City.

THE BOARD OF DIRECTORS, THE BOARD OF MANAGEMENT AND BOARD OF SUPERVISION

Members of the the Board of Directors during the year and to the reporting date are:

Mr. Do Thanh Trung	Chairman	(Appointed on April 18, 2025)
Mr. Nguyen Luong Tam	Chairman	(Resigned on April 18, 2025)
		(Appointed as a Member of the Board of Directors on April 18, 2025)
Mr. Nguyen Trung	Member	(Resigned on December 01, 2025)
Mr. Hoang Trung Dung	Member	
Mr. Vu Thien Tiep	Member	(Appointed on December 01, 2025)
Mrs. Dinh Thi Mong Van	Member	

Member of the the Board of Management operated the Company during the year and as at the reporting date are:

Mr. Nguyen Luong Tam	General Director	(Appointed on April 18, 2025)
Mr. Nguyen Trung	Deputy General Director	
Mr. Nguyen Ba Hai	Deputy General Director	

Members of the Board of Supervision are:

Mrs. Nguyen Thi Yen	Head of Board of Supervision
Mrs. Pham Thi Minh Ngoc	Member
Mrs. Nguyen Thi Thanh Thuy	Member

LEGAL REPRESENTATIVE

The legal representative of the Company during the year and until the preparation of these Financial Statements is Mr. Nguyen Luong Tam - General Director.

Mr. Nguyen Trung - Deputy General Director, is authorized by Mr. Nguyen Luong Tam to sign the Financial Statements for the fiscal year ended as at December 31, 2025, pursuant to Power of Attorney No. 575/UQ-CT dated April 28, 2025.

AUDITORS

The auditors of AASC Auditing Firm Company Limited have taken audit of Financial Statements for the Company.

STATEMENT OF THE THE BOARD OF MANAGEMENT'S RESPONSIBILITY IN RESPECT OF THE FINANCIAL STATEMENTS

The the Board of Management of the Company is responsible for the Financial Statements which give a true and fair view of the financial position of the Company, its operating results and its cash flows for the year. In preparing these Financial Statements, the the Board of Management of the Company is required to:

- Establish and maintain an internal control system which is determined necessary by the Board of Management and the Board of Directors to ensure the preparation and presentation of Financial Statements do not contain any material misstatement caused by errors or frauds;
- Select suitable accounting policies and then apply them consistently;
- Make judgments and estimates that are reasonable and prudent;
- State whether applicable accounting standards have been followed, subject to any material departures disclosed and explained in the Financial Statements;
- Prepare and present the Financial Statements on the basis of compliance with Vietnamese Accounting Standards, Vietnamese Corporate Accounting System and the statutory requirements relevant to preparation and presentation of the Financial Statements;
- Prepare the Financial Statements on the going concern basis unless it is inappropriate to presume that the Company will continue in business.

The the Board of Management of the Company is responsible for ensuring that accounting records are kept to reflect the financial position of the Company, with reasonable accuracy at any time and to ensure that the Financial Statements comply with the current State's regulations. It is responsible for safeguarding the assets of the Company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The the Board of Management of the Company confirms that Financial Statements give a true and fair view of the financial position of the Company as at 31 December 2025, its operation results and cash flows for the fiscal year end as at the same date in accordance with the Vietnamese Accounting Standards, Vietnamese Corporate Accounting System and the statutory requirements relevant to the preparation and presentation of Financial Statements.

Other commitments

The Board of Directors and Management pledges that the Company complies with the requirements of the Law on Securities, Decree No.155/2020/ND-CP dated December 31, 2020, and Decree No.245/2025/ND-CP dated September 11, 2025, amending Decree No.155/2020/ND-CP detailing the implementation of some articles of the Law on Securities, and that the Company has not violated its information disclosure obligations as stipulated in Circular No.96/2020/TT-BTC dated November 16, 2020, of the Ministry of Finance guiding information disclosure on the securities market, Circular No.68/2024/TT-BTC dated September 18, 2024, of the Ministry of Finance amending and supplementing some articles of the Circular No.96/2020/TT-BTC and Circular No.08/2026/TT-BTC dated February 3, 2026, amending and supplementing several articles of the Circular No.96/2020/TT-BTC and the Circular No.68/2024/TT-BTC.



On behalf of the the Board of Management

Nguyễn Trung

Deputy General Director

Da Nang, 25 March 2026

INDEPENDENT AUDITORS' REPORT

**To: Shareholders, the Board of Directors and the Board of Management
Danang Pharmaceutical - Medical Equipment Joint Stock Company**

We have audited the accompanying Financial Statements of the Danang Pharmaceutical - Medical Equipment Joint Stock Company prepared on 25 March 2026, from page 06 to page 43, including: Statement of Financial Position as at 31 December 2025, Statement of Income, Statement of Cash flows, Notes to the Financial Statements for the fiscal year ended as at 31 December 2025.

The Board of Management's Responsibility

The Board of Management is responsible for the preparation and presentation of Financial Statements that give a true and fair view in accordance with Vietnamese Accounting Standards, Vietnamese Corporate Accounting System and the statutory requirements relevant to the preparation and presentation of Financial Statements and for such internal control as Management determines is necessary to enable the preparation and presentation of Financial Statements that are free from material misstatement, whether due to fraud or error.

Auditor's Responsibility

Our responsibility is to express an opinion on these Financial Statements based on our audit. We conducted our audit in accordance with Vietnamese Standards on Auditing. Those standards require that we comply with standards and ethical requirements; plan and perform the audit to obtain reasonable assurance about whether the Financial Statements of the Company are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the Financial Statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the Financial Statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the Company's preparation and presentation of the Financial Statements that give a true and fair view in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of accounting estimates made by the Board of Management, as well as evaluating the overall presentation of the Financial Statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Auditor's Opinion

In our opinion, the Financial Statements give a true and fair view, in all material respects, of the financial position of Danang Pharmaceutical - Medical Equipment Joint Stock Company as at 31 December 2025, its operating results and its cash flows for the year then ended in accordance with the Vietnamese Accounting Standards, Vietnamese Corporate Accounting System and the statutory requirements relevant to the preparation and presentation of the Financial Statements.

Emphasis of Matter

We draw attention to Notes 5 and 16 to the financial statements, which describe certain trade receivables guaranteed by suppliers through tripartite payment guarantee agreements signed among the Company, the suppliers, and the customers.



AASC Auditing Firm Company Limited

Nguyen Ngoc Lan
Deputy General Director
Registered Auditor
No. 1427-2023-002-1
Hanoi, 26 March 2026

Nguyen Duc Trong
Auditor
Registered Auditor
No. 4062-2024-002-1

STATEMENT OF FINANCIAL POSITION

As at 31 December 2025

Code	ASSETS	Note	31/12/2025	01/01/2025
			VND	VND
100	A. CURRENT ASSETS		932,212,268,849	1,080,165,522,864
110	I. Cash and cash equivalents	03	31,329,191,997	29,127,572,681
111	1. Cash		31,329,191,997	29,127,572,681
120	II. Short-term investments	04	117,659,600,000	123,544,270,909
123	1. Held-to-maturity investments		117,659,600,000	123,544,270,909
130	III. Short-term receivables		656,827,723,867	751,533,989,814
131	1. Short-term trade receivables	05	617,674,825,101	678,163,741,281
132	2. Short-term prepayments to suppliers	06	24,211,305,039	32,531,365,975
135	3. Short-term loan receivables	07	28,100,000,000	54,100,000,000
136	4. Other short-term receivables	08	4,812,796,459	5,252,277,215
137	5. Provision for short-term doubtful debts		(17,971,202,732)	(18,513,394,657)
140	IV. Inventories	10	121,626,455,140	167,152,337,595
141	1. Inventories		121,691,947,620	167,874,687,651
149	2. Provision for devaluation of inventories		(65,492,480)	(722,350,056)
150	V. Other short-term assets		4,769,297,845	8,807,351,865
151	1. Short-term prepaid expenses	14	1,173,568,134	1,063,643,617
152	2. Deductible VAT		3,595,729,711	6,348,207,171
153	3. Taxes and other receivables from the State budget	18	-	1,395,501,077
200	B. NON-CURRENT ASSETS		88,425,358,135	92,596,742,193
220	I. Fixed assets		77,166,871,831	80,678,083,819
221	1. Tangible fixed assets	12	54,793,328,447	58,999,338,441
222	- Historical cost		82,606,424,721	83,110,038,277
223	- Accumulated depreciation		(27,813,096,274)	(24,110,699,836)
227	2. Intangible fixed assets	13	22,373,543,384	21,678,745,378
228	- Historical cost		24,789,553,541	23,760,184,541
229	- Accumulated amortization		(2,416,010,157)	(2,081,439,163)
240	II. Long-term assets in progress	11	1,325,960,059	1,939,045,712
242	1. Construction in progress		1,325,960,059	1,939,045,712
260	III. Other long-term assets		9,932,526,245	9,979,612,662
261	1. Long-term prepaid expenses	14	9,932,526,245	9,979,612,662
270	TOTAL ASSETS		<u>1,020,637,626,984</u>	<u>1,172,762,265,057</u>


STATEMENT OF FINANCIAL POSITION

As at 31 December 2025

(Continued)

Code	CAPITAL	Note	31/12/2025	01/01/2025
			VND	VND
300	C. LIABILITIES		813,500,332,073	969,000,078,856
310	I. Current Liabilities		810,771,632,073	966,518,478,856
311	1. Short-term trade payables	16	606,806,110,721	737,367,907,993
312	2. Short-term prepayments from customers	17	49,689,813,897	52,813,791,682
313	3. Taxes and other payables to State budget	18	498,817,771	366,835,492
314	4. Payables to employees		6,895,176,199	13,072,741,850
315	5. Short-term accrued expenses	19	225,152,626	92,978,488
318	6. Short-term unearned revenue	21	767,803,501	1,125,648,396
319	7. Other short-term payables	20	1,118,321,727	1,542,870,769
320	8. Short-term borrowings and finance lease liabilities	15	144,741,860,079	160,107,128,634
322	9. Bonus and welfare fund		28,575,552	28,575,552
330	II. Non-current liabilities		2,728,700,000	2,481,600,000
337	1. Other long-term payables	20	2,728,700,000	2,481,600,000
400	D. OWNER'S EQUITY		207,137,294,911	203,762,186,201
410	I. Owner's equity	22	207,137,294,911	203,762,186,201
411	1. Contributed capital		161,163,830,000	153,493,280,000
412	2. Share Premium		9,215,548,634	9,215,548,634
414	3. Other capital		2,334,190,178	2,334,190,178
418	4. Development and investment funds		25,644,628,267	25,644,628,267
421	5. Retained earnings		8,779,097,832	13,074,539,122
421a	Retained earnings accumulated to the previous		4,693,181,749	5,450,386,745
421b	Retained earnings of the current year		4,085,916,083	7,624,152,377
440	TOTAL CAPITAL		1,020,637,626,984	1,172,762,265,057

Preparer



Tran Khanh Linh

Chief Accountant



Tran Thi Anh Minh



STATEMENT OF INCOME

Year 2025

Code	ITEMS	Note	Year 2025	Year 2024
			VND	VND
01	1. Revenue from sales of goods and rendering of services	24	1,069,462,010,993	1,394,654,213,706
02	2. Revenue deductions	25	1,542,836,200	1,995,504,112
10	3. Net revenue from sales of goods and rendering of services		1,067,919,174,793	1,392,658,709,594
11	4. Cost of goods sold and services rendered	26	973,027,927,144	1,302,659,852,809
20	5. Gross profit from sales of goods and rendering of services		94,891,247,649	89,998,856,785
21	6. Financial income	27	32,252,962,616	22,172,868,410
22	7. Financial expense	28	31,939,965,266	20,201,461,009
23	<i>In which: Interest expense</i>		7,554,831,694	3,965,186,702
25	8. Selling expense	29	83,942,993,901	74,006,080,320
26	9. General and administrative expenses	30	9,308,443,912	15,255,405,409
30	10. Net profit from operating activities		1,952,807,186	2,708,778,457
31	11. Other income	31	4,598,959,670	7,566,289,091
32	12. Other expenses	32	1,204,431,145	611,800,521
40	13. Other profit		3,394,528,525	6,954,488,570
50	14. Total net profit before tax		5,347,335,711	9,663,267,027
51	15. Current corporate income tax expense	33	1,261,419,628	2,039,114,650
52	16. Deferred corporate income tax expense		-	-
60	17. Profit after corporate income tax		<u>4,085,916,083</u>	<u>7,624,152,377</u>
70	18. Basic earnings per share	34	<u>254</u>	<u>473</u>

Da Nang, 25 March 2026

Preparer

Chief Accountant

Deputy General Director



Tran Khanh Linh



Tran Thi Anh Minh




Nguyen Trung

STATEMENT OF CASH FLOWS

Year 2025
(Indirect method)

Code	ITEMS	Note	Year 2025	Year 2024
			VND	VND
I. CASH FLOWS FROM OPERATING ACTIVITIES				
01	1. Profit before tax		5,347,335,711	9,663,267,027
	2. Adjustment for		6,527,244,424	(5,474,544,857)
02	- Depreciation and amortization of fixed assets and investment properties		11,177,817,575	4,528,708,746
03	- Provisions		(1,199,049,501)	(769,881,723)
04	- Exchange gains/losses from retranslation of monetary items denominated in foreign currency		276,335,983	40,635,246
05	- Gains / losses from investment activities		(11,282,691,327)	(13,239,193,828)
06	- Interest expense		7,554,831,694	3,965,186,702
08	3. Operating profit before changes in working capital		11,874,580,135	4,188,722,170
09	- Increase/ decrease in receivables		82,797,282,960	(282,210,138,341)
10	- Increase/ decrease in inventories		46,182,740,031	(53,883,609,713)
11	- Increase/ decrease in payables (excluding interest payable/ corporate income tax payable)		(151,630,626,023)	342,474,465,043
12	- Increase/ decrease in prepaid expenses		(288,195,700)	(2,158,469,303)
14	- Interest paid		(7,422,657,556)	(4,013,292,024)
15	- Corporate income tax paid		(646,197,486)	(1,856,334,691)
16	- Other receipts from operating activities		-	1,080,000
20	Net cash flow from operating activities		(19,133,073,639)	2,542,423,141
II. CASH FLOWS FROM INVESTING ACTIVITIES				
21	1. Purchase or construction of fixed assets and other long-term assets		(6,206,388,263)	(12,389,582,125)
22	2. Proceeds from disposals of fixed assets and other long-term assets		825,453	7,780,392,591
23	3. Loans and purchase of debt instruments from other entities		(356,508,039,804)	(202,384,270,909)
24	4. Collection of loans and resale of debt instrument of other entities		388,392,710,713	127,800,000,000
27	5. Interest and dividend received		11,107,306,354	7,239,576,106
30	Net cash flow from investing activities		36,786,414,453	(71,953,884,337)
III. CASH FLOWS FROM FINANCING ACTIVITIES				
33	1. Proceeds from borrowings		955,221,755,065	884,954,644,376
34	2. Repayment of principal		(970,587,023,620)	(803,605,968,487)
40	Net cash flow from financing activities		(15,365,268,555)	81,348,675,889
50	Net cash flows in the year		2,288,072,259	11,937,214,693

STATEMENT OF CASH FLOWS

Year 2025
(Indirect method)

Code	ITEMS	Note	Year 2025	Year 2024
			VND	VND
60	Cash and cash equivalents at the beginning of the year		29,127,572,681	17,184,012,943
61	Effect of exchange rate fluctuations		(86,452,943)	6,345,045
70	Cash and cash equivalents at the end of the year		<u>31,329,191,997</u>	<u>29,127,572,681</u>

Da Nang, 25 March 2026

Preparer

Chief Accountant

Deputy General Director



Tran Khanh Linh



Tran Thi Anh Minh




Nguyen Trung

NOTES TO THE FINANCIAL STATEMENTS

Year 2025

1. GENERAL INFORMATION

Form of ownership

Danang Pharmaceutical - Medical Equipment Joint Stock Company was established and operates under the Business Registration Certificate of Joint Stock Company No. 0400101404 issued for the first time on March 22, 2005, amended for the 18th time on July 11, 2025 by Da Nang City Department of Planning and Investment (currently Da Nang City Department of Finance).

The Company's head office is located at: No. 02, Phan Dinh Phung Street, Hai Chau Ward, Da Nang City.

Charter capital of the Company is: VND 161163830000.; equivalent 16116383. shares, par value of share is VND 10,000.

The number of employees of the Company as at 31 December 2025 is: 211 people (as at 01 January 2025 is: 222 people).

Business field

Trading in pharmaceuticals, medicinal ingredients, traditional herbal products, vaccines, medical biological products and medical equipment.

Business activities

Main business activities of the Company include:

- Business - import and export: Pharmaceuticals, medicinal materials, chemicals, medical equipment and scientific supplies, nutritional and preventive foods, vaccines and biological products, mosquito repellent incense, mosquito spray, eyeglasses, cosmetics, various types of milk, candies, vitamin-enriched beverages, mineral water, and office supplies;
- Manufacture pharmaceuticals according to the list permitted by the Ministry of Health;
- Technology transfer and medical and scientific technical services: delivery, installation, user guidance, warranty, maintenance, and repair of medical and scientific equipment;
- Rental services: offices, warehouses.

The Company's operation in the period that affects the Financial Statements

- In 2025, due to the significant impact of exchange rate fluctuations on the imported pharmaceutical and medical equipment market, coupled with the inefficient operation of the distribution system and vaccination centers in Da Nang and Ho Chi Minh City, the Company's net revenue in 2025 decreased by VND 324.74 billion, a 23.32% reduction compared to the previous year. Additionally, the Company liquidated some real estate assets and recorded other income, resulting in a pre-tax profit of VND 5.488 billion in 2025, a 43.21% decrease compared to 2024.

Corporate structure

The Company's member entities are as	Address	Main business activities
Representative office	Hai Chau ward, Da Nang City	Pharmaceutical distribution
Ha Noi branch	Thanh Xuan ward, Ha Noi City	Pharmaceutical distribution
Ho Chi Minh City branch	Hoa Hung ward, Ho Chi Minh City	Pharmaceutical distribution

2. ACCOUNTING SYSTEM AND ACCOUNTING POLICY AT COMPANY

2.1. Accounting period and accounting currency

Annual accounting period commences from 1 January and ends as at 31 December.
The Company maintains its accounting records in Vietnam Dong (VND).

2.2. Standards and Applicable Accounting Policies

Applicable Accounting Policies

Company applies Corporate Accounting System issued under the Circular No. 200/2014/TT-BTC dated 22 December 2014 by the Ministry of Finance and the Circular No. 53/2016/TT-BTC dated 21 March 2016 issued by Ministry of Finance amending and supplementing some articles of the Circular No. 200/2014/TT-BTC.

Declaration of compliance with Accounting Standards and Accounting System

Company applies Vietnamese Accounting Standards and supplementary documents issued by the State. Financial Statements are prepared and presented in accordance with regulations of each standard and supplementary document as well as with current Accounting Standards and Accounting System.

2.3. Basis for the preparation of Financial Statements

The Financial Statement is prepared based on historical cost principle.

The Financial Statement of Company are prepared based on summarization of the financial statements of the dependent accounting entities and the head office of the Company.

In the Financial Statement of the Company, the intra-group balances and transactions related to assets, equity, receivables and payables... have been fully eliminated.

2.4. Accounting estimates

The preparation of Financial Statements in conformity with Vietnamese Accounting Standards, Vietnamese Corporate Accounting System and legal regulations relating to financial reporting requires the Board of Management to make estimates and assumptions that affect the reported amounts of liabilities, assets and disclosures of contingent liabilities and assets at the end of the the fiscal year and the reported amounts of revenues and expenses during the fiscal year.

The estimates and assumptions that have a material impact in the Financial Statements include:

- Provision for bad debts;
- Provision for devaluation of inventory;
- Estimated allocation of prepaid expenses;
- Estimated useful life of fixed assets;
- Classification and provision of financial investments;
- Estimated corporate income tax.

Such estimates and assumptions are continually evaluated. They are based on historical experience and other factors, including expectations of future events that may have a financial impact on Financial Statements of Company and that are assessed by the Board of Management of Company to be reasonable under the circumstance.

2.5. Financial Instruments

Initial recognition

Financial assets

Financial assets of Company include cash, cash equivalents, trade receivables and other receivables, lending loans, short-term and long-term investments. At initial recognition, financial assets are identified by purchasing price plus other expenses directly related to the purchase of those assets.

Financial liabilities

Financial liabilities of Company include borrowings, trade payables, other payables and accrued expenses. At initial recognition, financial liabilities are determined by issuing price plus other expenses directly related to the issuance of those liabilities.

Subsequent measurement after initial recognition

Financial assets and financial liabilities are not revalued according to fair value at the end of the fiscal year because the Circular No.210/2009/TT-BTC and prevailing statutory regulations require to present Financial statements and Notes to financial instruments but not provide any relevant instruction for assessment and recognition of fair value of financial assets and financial liabilities.

2.6. Foreign currency transactions

Foreign currency transactions during the fiscal year are translated into Vietnam Dong using the actual rate at transaction date.

Actual exchange rate when revaluating monetary items denominated in foreign currencies at the reporting date of Financial Statements is determined under the following principles:

- For asset accounts: Applying the bid rate of the commercial bank where Company regularly conducts transaction;
- For cash deposited in bank: Applying the bid rate of the commercial bank where Company opens its foreign currency accounts;
- For liability accounts: Applying the offer rate of the commercial bank where Company regularly conducts transactions.

All exchange differences arising as a result of transactions or revaluation at the balance sheet date will be recorded into the financial income or expense in the fiscal year.

2.7. Cash and cash equivalents

Cash includes cash on hand and demand deposits, and cash in transit.

Cash equivalents are short-term investments with the maturity of not over than 3 months from the date of investment, that are highly liquid and readily convertible into known amount of cash and that are subject to an insignificant risk of conversion into cash.

2.8. Financial investments

Investments held to maturity include term deposits at banks and certificates of deposit... held to maturity for the purpose of collecting periodic interest and other investments held to maturity.

The provision for impairment of investments held to maturity is made at the end of the year based on the recoverability to establish a provision for doubtful debts in accordance with statutory regulations.

2.9. Receivables

The receivables shall be recorded in details in terms of due date, entities receivable, types of currency and other factors according to requirements for management of Company. The receivables shall be classified into short-term receivables or long-term receivables on the Financial Statements according to their remaining terms at the reporting date.

The provision for doubtful debts is made for receivables that are overdue under an economic contract, a loan agreement, a contractual commitment or a promissory note and for receivables that are not due but difficult to be recovered. Accordingly, the provisions for overdue debts shall be based on the due date stipulated in the initial sale contract, exclusive of the debt rescheduling between contracting parties and the case where the debts are not due but the debtor is in bankruptcy, in dissolution, or missing and making fleeing or estimating the possible losses.

2.10. Inventories

Inventories are initially recognized at original cost including purchase price, processing cost and other costs incurred in bringing the inventories to their location and condition at the time of initial recognition. After initial recognition, at the reporting date, inventories are stated at the lower of cost and net realizable value.

For imported goods, the timing of inventory recognition is determined at the point when most of the risks and rewards associated with ownership of the products or goods have been transferred to the buyer in accordance with the delivery terms of Incoterms 2020.

Net realizable value is estimated based on the selling price of the inventory minus the estimated costs for completing the products and the estimated costs needed for their consumption.

The cost of inventory is calculated using weighted average method on a monthly basis for regular items that are not sold in batches and using the specific identification method for items sold in batches

Inventory is recorded by perpetual method.

Provision for devaluation of inventories made at the end of is based on the excess of original cost of inventory over their net realizable value.

2.11. Fixed assets

Fixed assets (tangible and intangible) are initially stated at the historical cost. During the using time, fixed assets (tangible and intangible) are recorded at cost, accumulated depreciation and carrying amount.

Subsequent measurement after initial recognition

If these costs augment future economic benefits obtained from the use of tangible fixed assets are extended to their initial standards conditions, these costs are capitalized as an incremental in their historical cost.

Other costs incurred after tangible fixed assets have been put into operation such as repair, maintenance and overhaul costs are recognized in the Statements of Income in the fiscal year in which the costs are incurred.

Fixed assets are depreciated (amortised) using the straight-line method over their estimated useful lives as follows:

- Buildings, structures	06 - 30 years
- Machinery, equipment	03 - 06 years
- Vehicles, Transportation equipment	05 - 10 years
- Office equipment and furniture	03 - 10 years
- Other fixed assets	03 years
- Management software	03 - 10 years
- Fixed term land use rights	50 years
- Indefinite land use rights	No amortization

There are some of the Company's buildings and structures are used both for owner-occupied purposes and for leasing. However, the leasing activity is only implemented in the short term, and the Company plans to carry out initial production and business activities on these assets in the near future. Therefore, the value of these buildings and structures is tracked by the Company under the Tangible Fixed Assets item.

2.12. Construction in progress

Construction in progress includes fixed assets which is being purchased and constructed as at the balance sheet date and is recognised in historical cost. This includes costs of construction, installation of equipment and other direct costs.

2.13. Operating lease

Operating leases is fixed asset leasing in which a significant portion of the risks and rewards of ownership are retained by the lessor. Payments made under operating leases are charged to Statement of Income on a straight-line basis over the period of the lease.

2.14. Prepaid expenses

The expenses incurred but related to operating results of several accounting periods are recorded as prepaid expenses and are allocated to the operating results in the following accounting periods.

The calculation and allocation of long-term prepaid expenses to operating expenses in each accounting period should be based on the nature of those expenses to select a reasonable allocation method and criteria.

Types of prepaid expenses of Company include:

- Prepaid land expenses include prepaid land rental, including those related to leased land for which the Company has received certificate of land use right but not eligible for recording as intangible fixed asset in accordance with the Circular No. 45/2013/TT-BTC dated 25 April 2013 issued by the Ministry of Finance guiding regulation on management, use and depreciation of fixed assets and other expenses related to ensure for the use of leased land. These expenses are recognized in the statement of income on a straight-line basis according to the lease term of the contract.
- Tools and supplies include assets which are possessed by the Company in an ordinary course of business, with historical cost of each asset less than 30 million dongs and and therefore not eligible for recording as fixed asset under current legal regulations. The historical cost of tools and supplies are allocated on the straight-line basis not exceeding 36 months.
- Other prepaid expenses are recorded at their historical costs and allocated on the straight-line basis not exceeding 36 months.

2.15. Payables

The payables shall be recorded in details in terms of due date, entities payable, types of currency and other factors according to the requirements for management of Company. The payables shall be classified into short-term payables or long-term payables on the Financial Statements according to their remaining terms at the reporting date.

2.16. Borrowings

Borrowings shall be recorded in details in terms of lending entities, loan agreement and terms of borrowings. In case of borrowings or liabilities denominated in foreign currency, they shall be recorded in details in terms of types of currency.

2.17. Borrowing costs

Borrowing costs are recognized as operating expenses in the year, in which it is incurred excepting those which are directly attributable to the construction or production of a qualifying asset are capitalized as part of the cost of that asset in accordance with VAS No. 16 "Borrowing costs". Besides, regarding borrowings serving the construction of fixed assets and investment properties, the interests shall be capitalized even when the construction duration is under 12 months.

2.18. Accrued expenses

Accrued expenses include payables to goods or services received from the suppliers or provided for the customers during the reporting period, but the payments for such goods or services have not been made and other payables which are recorded as operating expenses of the reporting year.

The recording of accrued expenses as operating expenses during the year shall be carried out under the matching principle between revenues and expenses during the year. Accrued expenses are settled with actual expenses incurred. The difference between accrued and actual expenses is reverted.

2.19. Unearned revenues

Unearned revenues include prepayments from customers for one or several accounting periods relating to asset leasing.

Unearned revenues are transferred to revenue from sale of goods and rendering of services with the amount corresponding to each accounting period.

2.20. Owner's equity

Owner's equity is stated at actually contributed capital of owners.

Share premium is recorded at the difference between the par value, the direct costs associated with the issuance of shares and issue price of shares (including the case of re-issuing treasury shares) and can be a positive premium (if the issue price is higher than par value and costs directly attributable to the issuance of shares) or negative premium (if the issue price is lower than par value and costs directly attributable to the issuance of shares).

Other capital is the operating capital formed from the operating results or from gifts, presents, financing, assets revaluation (if these items are allowed to be recorded as a decrease or increase in the owner's equity).

Dividends to be paid to shareholders are recognised as a payable in Statement of Financial position after the announcement of dividend payment from the Board of Directors of Company and announcement of cut-off date for dividend payment of Vietnam Securities Depository and Clearing Corporation.

2.21. Revenue

Revenue is recognized to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured regardless of when payment is being made.

Revenue is measured at the fair value of the consideration received excluding discounts, sales discounts, and sales returns. The following specific recognition conditions must also be met when recognizing revenue:

Revenue from sale of goods:

- The majority of risks and benefits associated with the right to own the products or goods have been transferred to the buyer;
- Company no longer holds the right to manage the goods as the goods owner, or the right to control the goods.

Revenue from rendering of services:

- The percentage of completion of the transaction at the Balance sheet date can be measured reliably .

Financial income

Financial incomes include income from assets yielding interest and other financial gains by the company shall be recognised when the two conditions are satisfied:

- It is probable that the economic benefits associated with the transaction will flow to the Company; and
- The amount of the revenue can be measured reliably.

2.22. Revenue deductions

Revenue deductions from sales of goods and rendering of services arising in the year include: Trade discounts, sales discounts and sales returns.

Trade discount, sales discount and sales return incurred in the same period of sale of goods and rendering of services are recorded as a decrease in revenue in the incurring period. In case goods and services are sold in the previous periods, but until the next period they are incurred as deductible items, the Company records the decrease in revenue under the following principles: If it is incurred prior to the issuance of Financial Statements, it is then recorded as a decrease in revenue on the Financial Statements of the reporting period (the previous period); and if it is incurred after the issuance of Financial Statements, it is recorded as a decrease in revenue of incurring period (the next period).

2.23. Cost of goods sold and services rendered

Cost of goods sold and services rendered are cost of finished goods, merchandises, materials sold or services rendered during the year, and recorded on the basis of matching with revenue and on a prudence basis. Cases of loss of materials and goods exceeded the norm, labour cost and fixed manufacturing overheads not allocated to the value of inventory, provision for devaluation of inventory, abnormal expenses and losses of inventories after deducting the responsibility of collective and individuals concerned, etc. is recognized fully and promptly into cost of goods sold in the year even when products and goods have not been determined as sold.

2.24. Financial expenses

Items recorded as financial expenses comprise:

- Borrowing costs;
- Losses from sale of foreign currency, exchange loss, etc.

The above items are recorded by the total amount arising in the year without offsetting against financial income.

2.25. Corporate income tax

a) Current corporate income tax expenses

Current corporate income tax expenses are determined based on taxable income during the year and current corporate income tax rate.

b) Current corporate income tax rate

The Company applies the corporate income tax rate of 20% for the operating activities which have taxable income for the fiscal year ended as at 31/12/2025.

2.26. Earnings per share

Basic earnings per share are calculated by dividing net profit or loss after tax for the year attributable to ordinary shareholders of Company (after adjusting for the bonus and welfare fund and allowance for Board of Management) by the weighted average number of ordinary shares outstanding during the year .

2.27. Related Parties

The parties are regarded as related parties if that party has the ability to control or significantly influence the other party in making decisions about the financial policies and activities. Company's related parties include:

- Companies, directly or indirectly through one or more intermediaries, having control over the Company or being under the control of Company, or being under common control with Company, including Company's parent, subsidiaries and associates;
- Individuals, directly or indirectly, holding voting power of Company that have a significant influence on Company, key management personnel including directors and employees of Company, the close family members of these individuals;
- Enterprises that the above-mentioned individuals directly or indirectly hold an important part of the voting power or have significant influence on these enterprises.

In considering the relationship of related parties to serve for the preparation and presentation of Financial Statements, Company should consider the nature of the relationship rather than the legal form of the relationship.

2.28. Segment information

Due to the Company primarily operates in the field of pharmaceuticals and medical equipment distribution and mainly within the territory of Vietnam, the Company does not prepare segment reports by business segment and geographical segment.

3. CASH

	31/12/2025	01/01/2025
	VND	VND
Cash on hand	225,562,108	80,608,843
Demand deposits	30,768,372,853	28,595,862,787
Cash in transit	335,257,036	451,101,051
	31,329,191,997	29,127,572,681

4. HELD-TO-MATURITY INVESTMENTS

	31/12/2025		01/01/2025	
	Original cost	Provision	Original cost	Provision
	VND	VND	VND	VND
- Term deposits (1)	117,659,600,000	-	62,484,270,909	-
- Certificates of deposit	-	-	61,060,000,000	-
	117,659,600,000	-	123,544,270,909	-

(1) As of December 31, 2025, the term deposits with maturities of less than 12 months, totaling of VND 117,659,600,000 are deposited at Vietnamese commercial banks and at VPBank SMBC Finance Company Limited.

As of December 31, 2025, some of the term deposits are used as collateral for the Company's loan (Detailed in Note 15), totaling 44,159,600,000 VND

5. SHORT-TERM TRADE RECEIVABLES

	31/12/2025		01/01/2025	
	Value	Provision	Value	Provision
	VND	VND	VND	VND
<i>Related parties</i>	-	-	-	-
<i>Others</i>	617,674,825,101	(17,971,202,732)	678,163,741,281	(18,513,394,657)
- Da Nang Hospital	5,535,930,555	-	3,874,516,480	-
- Hue Central Hospital	10,807,586,088	-	13,336,632,720	-
- Phuong Le Pharmaceutical and Medical	52,262,535,410	-	100,248,659,132	-
- EU Pharmaceutical Joint Stock Company (*)	2,379,904,619	-	18,514,541,742	-
- Cali - U.S.A Medicine Pharmacy Company Limited (*)	8,631,737,145	-	17,700,874,767	-
- S Pharmaceutical Company Limited (*)	30,818,606,395	-	10,738,461,976	-
- Hiep Thuan Thanh Medical Company Limited (*)	39,128,321,148	-	27,757,042,051	-
- Thai Nhan Pharmaceutical Cosmetics Company Limited (*)	31,363,615,529	-	70,359,953,887	-
- Gia Viet Pharmaceutical Trading Company Limited (*)	1,468,002,604	-	13,734,566,869	-
- Mr. Nguyen Hai Hung (**)	18,341,998,487	(10,911,001,197)	18,341,998,487	(10,911,001,197)
- Minh Tien Pharmaceutical Company Limited	5,385,033,068	(5,385,033,068)	6,135,033,068	(6,135,033,068)
- Other customers	411,551,554,053	(1,675,168,467)	377,421,460,102	(1,467,360,392)
	617,674,825,101	(17,971,202,732)	678,163,741,281	(18,513,394,657)

As of December 31, 2025, the receivables arising from loans of Bank for Investment and Development of Vietnam – Song Han Branch and Vietnam Joint Stock Commercial Bank for Industry and Trade were pledged as collateral for the loans at these banks (Details in Note 15).

(*) Some receivables from customers guaranteed by suppliers through a tripartite payment guarantee agreement signed between the Company, the suppliers and the customers, and other collateral. Accordingly, the Company only has to pay the suppliers after receiving payments from the guaranteed customers. As of December 31, 2025, the Company's receivables from the guaranteed customers correspond to the payables to suppliers used for guarantee with value of VND 425,975,635,090.

(**) Customer receivables are secured by a land plot in Son Tra ward, Da Nang city.

6. SHORT-TERM PREPAYMENTS TO SUPPLIERS

	31/12/2025		01/01/2025	
	Value	Provision	Value	Provision
	VND	VND	VND	VND
<i>Related parties</i>	-	-	-	-
<i>Others</i>	24,211,305,039	-	32,531,365,975	-
- Asian Dimedical Pte Ltd	1,178,847,833	-	1,178,847,833	-
- Saint Corporation	4,733,926,442	-	1,414,173,492	-
- Inbiotech L.T.D	1,041,852,001	-	8,595,194,613	-
- H&B Pharma International INC	-	-	6,606,048,918	-
- Growena Impex Company - HCM	3,821,265,000	-	-	-
- Nguyen Phu Dung	2,295,000,000	-	-	-
- Other prepayments to suppliers	11,140,413,763	-	14,737,101,119	-
	24,211,305,039	-	32,531,365,975	-

7. SHORT-TERM LOAN RECEIVABLES

	01/01/2025		During the period		31/12/2025	
	Value	Provision	Increase	Decrease	Value	Provision
	VND	VND	VND	VND	VND	VND
<i>Related parties</i>	54,100,000,000	-	126,000,000,000	152,200,000,000	27,900,000,000	-
- Elmich Joint Stock Company	54,100,000,000	-	126,000,000,000	152,200,000,000	27,900,000,000	-
<i>Others</i>	-	-	200,000,000	-	200,000,000	-
- QA Medical Equipment Limited	-	-	200,000,000	-	200,000,000	-
	54,100,000,000	-	126,200,000,000	152,200,000,000	28,100,000,000	-

Detail of loan receivables are as follows:

	Contract No.	Currency	Purpose of borrowing	Interest rate	Maturity date	Guarantee	31/12/2025	01/01/2025
							VND	VND
<i>Related parties</i>							27,900,000,000	54,100,000,000
Elmich Joint Stock Company	Contract No. 01/2025/DAP-ELM; 02/2025/DAP-ELM; 03/2025/DAP-ELM; 04/2025/DAP-ELM; 05/2025/DAP-ELM; 06/2025/DAP-ELM; 07/2025/DAP-ELM; 08/2025/DAP-ELM	VND	Serving production and business	Per each disbursement agreement	6 months	Unsecured	27,900,000,000	54,100,000,000
<i>Others</i>							200,000,000	-
QA Medical Equipment Limited	01/2025/DAP-QA	VND	Serving production and business	Per each disbursement agreement	To 31/03/2026	Unsecured	200,000,000	-
							28,100,000,000	54,100,000,000

8. OTHER RECEIVABLES

	31/12/2025		01/01/2025	
	Value	Provision	Value	Provision
	VND	VND	VND	VND
a.1) Details by content				
- Loan interest and deposit interest	3,410,616,406	-	3,236,056,886	-
- Mortgages	1,088,338,654	-	1,545,887,376	-
- Other receivables	313,841,399	-	470,332,953	-
	4,812,796,459	-	5,252,277,215	-
a.2) Detail by object				
<i>Related parties</i>	<i>741,946,846</i>	<i>-</i>	<i>725,713,699</i>	<i>-</i>
- Elmhich Joint Stock Company	741,946,846	-	725,713,699	-
<i>Others</i>	<i>4,070,849,613</i>	<i>-</i>	<i>4,526,563,516</i>	<i>-</i>
- VPBank SMBC Finance Company Limited	364,586,302	-	1,289,836,164	-
- Vietnam Export Import Commercial Joint Stock Bank (Eximbank)	-	-	242,906,474	-
- Saigon – Hanoi Commercial Joint Stock Bank (SHB)	1,032,767,124	-	199,452,055	-
- Viet Nam Joint Stock Commercial Bank For Industry And Trade	42,644,384	-	42,644,384	-
- Vietnam Prosperity Joint Stock Commercial Bank	686,863,016	-	641,493,151	-
- Joint Stock Commercial Bank for Investment and Development of Vietnam	97,959,419	-	94,010,959	-
- Vietnam Technological and Commercial Joint stock Bank (Techcombank)	343,972,603	-	-	-
- QA Medical Equipment Limited	936,986	-	-	-
- Ho Chi Minh City Development Joint Stock Commercial Bank	98,939,726	-	-	-
- Other customers	1,402,180,053	-	2,016,220,329	-
	4,812,796,459	-	5,252,277,215	-

9. DOUBTFUL DEBTS

	31/12/2025		01/01/2025	
	Original cost	Recoverable value	Original cost	Recoverable value
	VND	VND	VND	VND
- Total value of receivables and debts that are overdue or not due but are difficult to be recovered				
+ <i>Trade receivables</i>	25,473,008,586	7,501,805,854	26,022,216,918	7,508,822,261
- Quang Ngai Pharmaceutical - Medical Supplies State-owned Company Limited	917,826,085	-	917,826,085	-
- Mr. Nguyen Hai Hung	18,341,998,487	7,430,997,290	18,341,998,487	7,430,997,290
- Quang Nam Medical College	297,880,569	-	297,880,569	-
- Minh Tien Pharmaceutical Company	5,385,033,068	-	6,135,033,068	-
- Others	530,270,377	70,808,564	329,478,709	77,824,971
	<u>25,473,008,586</u>	<u>7,501,805,854</u>	<u>26,022,216,918</u>	<u>7,508,822,261</u>

10. INVENTORIES

	31/12/2025		01/01/2025	
	Original cost	Provision	Original cost	Provision
	VND	VND	VND	VND
- Goods in transit	50,242,223,719	-	125,147,795,016	-
- Raw materials	3,119,376,237	-	3,334,548,587	-
- Finished goods	1,850,674,231	-	1,992,099,654	-
- Goods	66,479,673,433	(65,492,480)	37,400,244,394	(722,350,056)
	<u>121,691,947,620</u>	<u>(65,492,480)</u>	<u>167,874,687,651</u>	<u>(722,350,056)</u>

As of December 31, 2025, the cost of inventory formed from loans from the Bank for Investment and Development of Vietnam – Song Han Branch and Vietnam Joint Stock Commercial Bank for Industry and Trade was pledged as collateral for loans at these banks (see Note 15 for details).

11. CONSTRUCTION IN PROGRESS

	31/12/2025	01/01/2025
	VND	VND
- <i>Purchase</i>	427,500,800	1,354,180,168
+ Storage rack system at Hoa Cam warehouse	-	1,236,880,168
+ Others	427,500,800	117,300,000
- <i>Construction in progress</i>	898,459,259	584,865,544
+ Repair and renovation	898,459,259	584,865,544
	<u>1,325,960,059</u>	<u>1,939,045,712</u>

12. TANGIBLE FIXED ASSETS

	Buildings, structures VND	Machinery, equipment VND	Vehicles, transportation equipment VND	Fixed assets used in management VND	Other tangible fixed assets VND	Total VND
Historical cost						
Beginning balance of the year	65,633,267,262	9,010,543,628	4,573,893,014	2,677,225,887	1,215,108,486	83,110,038,277
- Purchase in the year	-	468,538,095	324,675,630	-	888,320,909	1,681,534,634
- Completed construction investment	4,811,337,082	-	-	-	-	4,811,337,082
- Liquidation, disposal	(6,772,891,272)	-	(223,594,000)	-	-	(6,996,485,272)
Ending balance of the year	63,671,713,072	9,479,081,723	4,674,974,644	2,677,225,887	2,103,429,395	82,606,424,721
Accumulated depreciation						
Beginning balance of the year	14,959,852,821	2,705,681,511	4,295,481,896	1,286,193,127	863,490,481	24,110,699,836
- Depreciation in the year	9,238,327,083	993,919,951	73,770,629	256,650,965	55,220,353	10,617,888,981
- Liquidation, disposal	(6,772,891,272)	-	(142,601,271)	-	-	(6,915,492,543)
Ending balance of the year	17,425,288,632	3,699,601,462	4,226,651,254	1,542,844,092	918,710,834	27,813,096,274
Net carrying amount						
Beginning balance of the year	50,673,414,441	6,304,862,117	278,411,118	1,391,032,760	351,618,005	58,999,338,441
Ending balance of the year	46,246,424,440	5,779,480,261	448,323,390	1,134,381,795	1,184,718,561	54,793,328,447

- The carrying amount of tangible fixed assets pledged as collaterals for borrowings at the end of the year: VND 10,507,216,053.
- Cost of fully depreciated tangible fixed assets but still in use at the end of the year: VND 16,463,651,448.

13. INTANGIBLE FIXED ASSETS

	Land use rights	Computer software	Total
	VND	VND	VND
Historical cost			
Beginning balance of the year	19,975,925,041	3,784,259,500	23,760,184,541
- Purchase in the year	-	1,029,369,000	1,029,369,000
Ending balance of the year	19,975,925,041	4,813,628,500	24,789,553,541
Accumulated amortization			
Beginning balance of the year	55,993,172	2,025,445,991	2,081,439,163
- Amortization in the year	3,503,820	331,067,174	334,570,994
Ending balance of the year	59,496,992	2,356,513,165	2,416,010,157
Net carrying amount			
Beginning balance	19,919,931,869	1,758,813,509	21,678,745,378
Ending balance	19,916,428,049	2,457,115,335	22,373,543,384

- Carrying amount of intangible fixed assets pledged as collaterals for borrowings at the end of the year: VND 13,519,337,784.
- Cost of fully amortized intangible fixed assets but still in use at the end of the year: VND 1,980,710,500.

14. PREPAID EXPENSES

	31/12/2025	01/01/2025
	VND	VND
a) Short-term		
- Rental Costs	155,142,654	164,363,636
- Insurance costs	269,830,909	81,525,910
- Repair and Renovation Costs	32,247,495	1,133,331
- Others	716,347,076	816,620,740
	1,173,568,134	1,063,643,617
b) Long-term		
- Prepaid Land Lease - Hoa Cam Industrial Zone (*)	6,441,471,335	6,666,828,935
- Dispatched tools and supplies	2,203,830,184	1,012,859,945
- Repair Costs	846,376,818	619,719,284
- Others	440,847,908	1,680,204,498
	9,932,526,245	9,979,612,662

(*) One-time prepaid land rental at Hoa Cam Industrial Zone - Da Nang City for an area of 9,000 m² to serve the construction of the GSP warehouse system. As of December 31, 2025, the remaining lease term is 28 years and 8 months. The land rental cost allocated to expenses during the period is VND 225,357,600.

15. SHORT-TERM BORROWINGS

	01/01/2025		During the year		31/12/2025	
	Outstanding balance	Amount can be paid	Increase	Decrease	Outstanding balance	Amount can be paid
	VND	VND	VND	VND	VND	VND
- Joint Stock Commercial Bank for Investment and Development of Vietnam - Song Han Branch (1)	74,772,478,104	74,772,478,104	340,326,205,230	331,876,885,089	83,221,798,245	83,221,798,245
+ Vietnam Joint Stock Commercial Bank for Industry and Trade - Da Nang Branch (2)	85,304,650,530	85,304,650,530	517,910,163,124	565,826,750,641	37,388,063,013	37,388,063,013
+ Joint Stock Commercial Bank For Foreign Trade Of Vietnam - Da Nang Branch (3)	-	-	96,925,386,711	72,853,387,890	24,071,998,821	24,071,998,821
+ Individual loan	30,000,000	30,000,000	60,000,000	30,000,000	60,000,000	60,000,000
	160,107,128,634	160,107,128,634	955,221,755,065	970,587,023,620	144,741,860,079	144,741,860,079

Detailed information on Short-term borrowings:

Detailed information on Short-term borrowings from banks and credit institutions is as follows:

	Contract No.	Currency	Interest rate	Date due	Loan purpose	Guarantee	31/12/2025	01/01/2025
							VND	VND
Others							144,741,860,079	160,107,128,634
(1) Joint Stock Commercial Bank for Investment and Development of Vietnam - Song Han Branch (1)	Contract No.01/2025/7609338/HĐT D	VND	Per loan agreement	Under 6 months	Supplement working capital	1.1	83,221,798,245	74,772,478,104
(2) Vietnam Joint Stock Commercial Bank for Industry and Trade - Da Nang Branch (2)	Contract No.01/2024-HĐCVHM/NHCT480-DAPHARCO	VND	Per loan agreement	Under 6 months	Supplement working capital	2.1	37,388,063,013	85,304,650,530

	Contract No.	Currency	Interest rate	Date due	Loan purpose	Guarantee	31/12/2025	01/01/2025
(3) Joint Stock Commercial Bank For Foreign Trade Of Vietnam - Da Nang Branch (3)	Contract No.80/2025/CTD/VCB-KHDN	VND	Per loan agreement	Under 6 months	Supplement working capital	3.1	24,071,998,821	-
(4) Individual loan		VND	Per loan agreement	Per loan agreement	Supplement working capital	Unsecured	60,000,000	30,000,000
							<u>144,741,860,079</u>	<u>160,107,128,634</u>

(1.1) Mortgage by the borrower's assets includes inventory, accounts receivable formed from loan capital, term deposit contracts and land use rights under asset mortgage contracts, including:

- + Mortgage of Land Use Rights and assets attached to land according to Real Estate Mortgage Contract No. 0007.14/HDTC dated February 28, 2014 and the Document No. 01/2016/7609338/SĐBS dated December 30, 2016, amending and supplementing the Mortgage Contract;
- + Asset Mortgage Contract No. 04/2024/7609338/HĐBĐ dated November 28, 2024;
- + Pledge of inventory, receivables formed from loan proceeds and term deposit contracts.

(2.1) Pledge of the borrower's assets such as inventories, receivables formed from loan proceeds and Land Use Rights under the Asset Mortgage Contracts, including:

- + Asset Mortgage Contract No. QN062010/HDTC dated September 21, 2010;
- + Asset Mortgage Contract No. 07130901/HDTC dated April 8, 2008;
- + Asset Mortgage Contract No. 06130902/HDTC dated November 6, 2006;
- + Asset Mortgage Contract No. 06130901/HDTC dated November 6, 2006;

+ Pledge of inventory, receivables formed from loan proceeds.

(3.1) Pledge of the borrower's assets, which are inventory, receivables formed from loan proceeds under Mortgage Contracts, including:

- + Deposit Pledge Agreement No 50/2025/VCB-ĐN dated March 17, 2025;
- + Pledge of inventory, receivables formed from loan proceeds.

Loans from banks and other credit institutions have been secured by mortgage contracts with lenders and have been fully registered for secured transactions.

16. SHORT-TERM TRADE PAYABLES

	31/12/2025		01/01/2025	
	Outstanding balance	Amount can be paid	Outstanding balance	Amount can be paid
	VND	VND	VND	VND
<i>Related parties</i>	-	-	27,843,750	27,843,750
- Megram Joint Stock Company	-	-	27,843,750	27,843,750
<i>Others</i>	606,806,110,721	606,806,110,721	737,340,064,243	737,340,064,243
- Inbiotech L.T.D (*)	8,250,991,159	8,250,991,159	33,969,559,659	33,969,559,659
- Axon Drugs Private Ltd	5,468,719,314	5,468,719,314	18,109,218,894	18,109,218,894
- Delta Pharma Limited (*)	-	-	42,868,880,451	42,868,880,451
- Prime Pharmaceutical Limited (*)	13,502,913,840	13,502,913,840	13,080,067,920	13,080,067,920
- Growena Impex Company (*)	-	-	31,916,233,301	31,916,233,301
- Incepta Pharmaceuticals Ltd (*)	39,632,807,510	39,632,807,510	78,833,726,748	78,833,726,748
- Bliss Pharma Distribution and Consultancy Corp. (*)	86,401,450,763	86,401,450,763	27,156,116,608	27,156,116,608
- Others	453,549,228,135	453,549,228,135	491,406,260,662	491,406,260,662
	<u>606,806,110,721</u>	<u>606,806,110,721</u>	<u>737,367,907,993</u>	<u>737,367,907,993</u>

(*) Some trade payables guaranteed by suppliers for customer receivables through a tripartite payment guarantee agreement signed between the Company, the supplier, and the customer. Accordingly, the Company is only required to make payments to the suppliers after receiving payments from the guaranteed customers. See Note 5 for more details.

17. SHORT-TERM PREPAYMENTS FROM CUSTOMERS

	31/12/2025	01/01/2025
	VND	VND
<i>Related parties</i>	-	-
<i>Others</i>	49,689,813,897	52,813,791,682
- Thien An Pharmaceutical Company Limited	8,826,070,083	7,764,215,946
- Da Phuc Pharmaceutical Company Limited	9,600,000,000	9,676,122,972
- Lien Mai Pharmaceutical Company Limited	-	5,450,924,050
- Other suppliers	31,263,743,814	29,922,528,714
	<u>49,689,813,897</u>	<u>52,813,791,682</u>

18. TAX AND OTHER PAYABLES TO THE STATE BUDGET

	Opening receivable	Opening payables	Payables in the year	Actual payment in the year	Closing receivables	Tax payable at the end of the year
	VND	VND	VND	VND	VND	VND
- Value-added tax	270,410,963	14,810,304	83,363,067,288	83,015,462,143	-	92,004,486
- Export, import duties	-	-	10,539,504,176	10,539,504,176	-	-
- Corporate income tax	1,125,090,114	-	1,827,258,872	646,197,486	-	55,971,272
- Personal income tax	-	352,025,188	3,783,079,096	3,784,262,271	-	350,842,013
- Land tax and land rental	-	-	303,325,571	303,325,571	-	-
- Fees, charges and other payables	-	-	42,046,000	42,046,000	-	-
	<u>1,395,501,077</u>	<u>366,835,492</u>	<u>99,858,281,003</u>	<u>98,330,797,647</u>	<u>-</u>	<u>498,817,771</u>

The company's tax settlements are subject to examination by the tax authorities. Because the application of tax laws and regulations on many types of transactions is susceptible to varying interpretations, amounts reported in the Financial Statements could be changed at a later date upon final determination by the tax authorities.

19. SHORT-TERM ACCRUED EXPENSES

	31/12/2025	01/01/2025
	VND	VND
- Interest expense	225,152,626	92,978,488
	225,152,626	92,978,488

20. OTHER PAYABLES

	31/12/2025	01/01/2025
	VND	VND
a) Short-term payables		
a.1) Details by content		
- Surplus of assets awaiting resolution	102,342,285	70,478,826
- Trade union fee	78,882,319	76,721,942
- Social insurance	29,565,447	28,369,284
- Short-term deposits, collateral received	424,000,000	415,000,000
- Other payables	483,531,676	952,300,717
<i>Remuneration for the Board of Directors and the Supervisory Board</i>	96,500,000	470,000,000
<i>Others</i>	387,031,676	482,300,717
	1,118,321,727	1,542,870,769
a.2) Details by object		
- Social insurance of Da Nang City	29,565,447	28,369,284
- Other objects	1,088,756,280	1,514,501,485
	1,118,321,727	1,542,870,769
b) Long-term payables		
b.1) Details by content		
- Long-term deposits, collateral received	2,728,700,000	2,481,600,000
	2,728,700,000	2,481,600,000
b.2) Details by object		
- GIMGAMED Pharmaceutical Company Limited	1,500,000,000	1,500,000,000
- Buymed Logistics Company Limited	-	787,725,000
- GONSA Joint Stock Company	825,000,000	-
- Other objects	403,700,000	193,875,000
	2,728,700,000	2,481,600,000

21. SHORT-TERM UNEARNED REVENUES

	31/12/2025	01/01/2025
	VND	VND
- Receivable revenue from leasing premises (*)	767,803,501	1,125,648,396
	<u>767,803,501</u>	<u>1,125,648,396</u>

(*) Revenue received in advance from leasing premises at Cam Le Ward, Da Nang City and in Hai Chau Ward, Da Nang City.

22. OWNER'S EQUITY

a) Changes in owner's equity

	Contributed capital	Share premium	Other capital	Development and investment funds	Retained earnings	Total
	VND	VND	VND	VND	VND	VND
Beginning balance of previous year	153,493,280,000	9,215,548,634	2,334,190,178	25,644,628,267	5,450,386,745	196,138,033,824
Profit for previous year	-	-	-	-	7,624,152,377	7,624,152,377
Ending balance of previous year	<u>153,493,280,000</u>	<u>9,215,548,634</u>	<u>2,334,190,178</u>	<u>25,644,628,267</u>	<u>13,074,539,122</u>	<u>203,762,186,201</u>
Beginning balance of current year	153,493,280,000	9,215,548,634	2,334,190,178	25,644,628,267	13,074,539,122	203,762,186,201
Increase in capital in current year	7,670,550,000	-	-	-	-	7,670,550,000
Profit for current year	-	-	-	-	4,085,916,083	4,085,916,083
Distribution of dividends by shares	-	-	-	-	(7,670,550,000)	(7,670,550,000)
Other decrease	-	-	-	-	(710,807,373)	(710,807,373)
Ending balance of this year	<u>161,163,830,000</u>	<u>9,215,548,634</u>	<u>2,334,190,178</u>	<u>25,644,628,267</u>	<u>8,779,097,832</u>	<u>207,137,294,911</u>

According to the Resolution No. 10/2025/NQ-ĐHĐCĐ dated April 18, 2025 issued by Annual General Meeting of Shareholders, the Company announced the distribution of profits for 2024 as follows:

- Total number of shares issued: 767,466 shares;
- Total value of issued shares at par value: VND 7,674,660,000;
- Offering target: The Company's existing shareholders whose names are on the list as of the final registration date for exercising the right to receive stock dividends;
- Exercise ratio: 100:5 (On the record date for shareholders to exercise their rights, shareholders owning 100 shares will receive a dividend of 5 newly issued shares, corresponding to a stock dividend ratio of 5%);
- Rounding principle and handling of fractional shares: The number of shares issued to pay dividends to each shareholder will be rounded down to the nearest whole number; any fractional shares (if any) will be canceled and not processed.
- Funding source: Undistributed after-tax profits as of December 31, 2024, based on the audited financial statements for 2024.

The Company completed the issuance of shares to pay dividends on June 13, 2025, according to the Report on the results of the share issuance to pay dividends No. 850/BC-CT published on June 23, 2025, and completed the registration of the change to the Business Registration Certificate on July 11, 2025.

On July 14, 2025, the Company received certification for adjusting the registered share number information - ticker symbol DDN - at the Vietnam Securities Depository and Clearing Corporation. On July 24, 2025, the Company received approval for changing the trading registration of shares of Da Nang Pharmaceutical and Medical Equipment Joint Stock Company at the Hanoi Stock Exchange.

b) Details of Contributed capital

	Ending the year	Rate	Beginning the year	Rate
	VND	%	VND	%
Megram Joint Stock Company	82,204,690,000	51.01	78,290,190,000	51.01
Danapha Pharmaceutical Joint Stock Company	11,547,800,000	7.17	10,997,910,000	7.17
Mr. Pham Van Truong	-	-	10,050,000,000	6.55
Mr. Vu Thien Tiep	10,900,000,000	6.76	-	-
Others	56,511,340,000	35.06	54,155,180,000	35.27
	161,163,830,000	100.00	153,493,280,000	100.00

c) Capital transactions with owners and distribution of dividends and profits

	Year 2025	Year 2024
	VND	VND
Owner's contributed capital		
- At the beginning of the year	153,493,280,000	153,493,280,000
- Increase in the year	7,670,550,000	-
- At the end of the year	161,163,830,000	153,493,280,000

d) Share

	31/12/2025	01/01/2025
Quantity of Authorized issuing shares	16,116,383	15,349,328
Number of shares issued and fully paid	16,116,383	15,349,328
- Common shares	16,116,383	15,349,328
Quantity of outstanding shares in circulation	16,116,383	15,349,328
- Common shares	16,116,383	15,349,328
Par value per share (VND):	10,000	10,000

e) The Company's reserves

	31/12/2025	01/01/2025
	VND	VND
- Development and investment funds	25,644,628,267	25,644,628,267
	<u>25,644,628,267</u>	<u>25,644,628,267</u>

23. OFF STATEMENT OF FINANCIAL POSITION ITEMS AND OPERATING LEASE COMMITMENT

a) Operating asset for leasing

The Company is currently leasing a property as a house located at 06 Tran Quoc Toan Street, Hai Chau 1 Ward, Da Nang City, with an area of 400.6 m2 under an operating lease agreement valid until September 9, 2027.

The Company has signed a warehouse lease agreement at Hoa Cam Industrial Park - Da Nang City with a total area of 2,127.6 m2 under an operating lease agreement valid until October 15, 2030.

b) Operating leased assets

The Company has signed contracts on leasing land at Da Nang City for the purposes of building working offices, retail product stores and warehouses. Under these contracts, the Company is required to pay annual land rental fees until the contract expiration date, in accordance with the prevailing regulations of the State.

The Company has signed a contract on leasing a land at Hoa Cam Industrial Park - Da Nang City with an area of 9,000 m2 to build a drug storage warehouse and a medical supplies factory. The Company has paid the land rent once for the lease period from January 2019 to August 2054.

c) Assets held under trust

The Company is accepting assets from some customers as collateral to secure the customer receivable, including: Inventory lots which are stored at the Hanoi Branch and Ho Chi Minh City Branch with total value of VND 45,730,865,498

d) Foreign currencies

	Unit	31/12/2025	01/01/2025
- US Dollars (\$)	USD	18,916.51	18,640.87
- Euro (€)	EUR	200.22	309.32

24. TOTAL REVENUE FROM SALES OF GOODS AND RENDERING OF SERVICES

	Year 2025	Year 2024
	VND	VND
Revenue from sales of goods	973,599,558,023	1,305,216,939,820
Revenue from sales of finished goods	16,925,437,018	22,112,986,381
Revenue from rendering of services	78,937,015,952	67,324,287,505
	<u>1,069,462,010,993</u>	<u>1,394,654,213,706</u>
In which: Revenue from related parties	-	2,639,343
(Detailed in Note 40)		

25. REVENUE DEDUCTIONS

	Year 2025	Year 2024
	VND	VND
- Trade discounts	1,404,722,118	1,585,711,379
- Sale discounts	12,602,654	99,027,699
- Sale returns	125,511,428	310,765,034
	1,542,836,200	1,995,504,112

26. COST OF GOODS SOLD

	Year 2025	Year 2024
	VND	VND
Cost of goods sold	938,717,401,491	1,271,195,890,616
Cost of finished goods sold	12,928,929,154	18,952,205,408
Cost of services rendered	22,038,454,075	13,431,172,815
Provision/Reversal of provision for devaluation of inventories	(656,857,576)	(919,416,030)
	973,027,927,144	1,302,659,852,809

In which: Purchase from related parties
(Detailed in Note 40)

	-	49,090,909
--	---	------------

27. FINANCIAL INCOME

	Year 2025	Year 2024
	VND	VND
Interest income	11,281,865,874	8,398,205,867
Gain on exchange difference in the year	19,555,603,064	12,487,324,355
Interest from deferred payment sale or payment discount	1,415,493,678	1,287,338,188
	32,252,962,616	22,172,868,410

In which: Financial income received from related parties
(Detailed in Note 40)

	4,213,599,995	1,398,543,836
--	---------------	---------------

28. FINANCIAL EXPENSES

	Year 2025	Year 2024
	VND	VND
Interest expenses	7,554,831,694	3,965,186,702
Loss on exchange difference in the year	24,051,489,940	16,145,313,590
Loss on exchange difference at the year- end	276,335,983	40,635,246
Other financial expenses	57,307,649	50,325,471
	31,939,965,266	20,201,461,009

29. SELLING EXPENSES

	Year 2025	Year 2024
	VND	VND
Labour expenses	40,881,511,327	46,825,585,701
Depreciation expenses	10,508,212,219	2,695,299,414
Expenses of outsourcing services	18,580,729,507	16,449,114,382
Other expenses in cash	13,972,540,848	8,036,080,823
	83,942,993,901	74,006,080,320

30. GENERAL AND ADMINISTRATIVE EXPENSE

	Year 2025	Year 2024
	VND	VND
Labour expenses	6,632,718,371	8,017,181,385
Depreciation expenses	60,223,558	1,061,570,304
Provision expenses/ Reversal of provision for receivables	(542,191,925)	149,534,307
Expenses of outsourcing services	1,236,464,928	2,666,255,690
Other expenses in cash	1,921,228,980	3,360,863,723
	9,308,443,912	15,255,405,409

In which: General and administrative expenses purchased from related parties
(Detailed in Note 40)

	14,857,066	56,667,140
--	------------	------------

31. OTHER INCOME

	Year 2025	Year 2024
	VND	VND
Gain from liquidation, disposal of fixed assets	825,453	4,840,987,961
Collected fines	7,500,000	1,002,240
Sales bonus, discounts and sales programs from suppliers	3,559,551,713	2,340,585,316
Others	1,031,082,504	383,713,574
	4,598,959,670	7,566,289,091

32. OTHER EXPENSES

	Year 2025	Year 2024
	VND	VND
Remuneration of non-executive members of Board of Directors	83,000,000	170,000,000
Others	1,121,431,145	441,800,521
	1,204,431,145	611,800,521

33. CURRENT CORPORATE INCOME TAX EXPENSES

	Year 2025	Year 2024
	VND	VND
Total profit before tax	5,347,335,711	9,663,267,027
Increase	959,762,427	532,306,223
- <i>Ineligible expenses</i>	959,762,427	532,306,223
Taxable income	6,307,098,138	10,195,573,250
Current corporate income tax expense (tax rate 20%)	1,261,419,628	2,039,114,650
Adjustment of tax expenses from previous years to current year	565,839,244	-
Tax payable at the beginning of the year	(1,125,090,114)	(1,307,870,073)
Tax paid in the year	(646,197,486)	(1,856,334,691)
Corporate income tax payable at the the year-end from business activities	55,971,272	(1,125,090,114)

34. BASIC EARNINGS PER SHARE

Basic earnings per share distributed to common shareholders of Company are calculated as follows:

	Year 2025	Year 2024 (Adjusted)
	VND	VND
Net profit after tax	4,085,916,083	7,624,152,377
Profit distributed to common shares	4,085,916,083	7,624,152,377
Average number of outstanding common shares in circulation in the year	16,116,383	16,116,383
Basic earnings per share	254	473

The Company has not planned to make any distribution to Bonus and welfare fund, bonus for the Board of Management from the net profit after tax at the date of preparing Financial Statements.

Basic earnings per share have been adjusted retrospectively as regulated by the Vietnamese Accounting Standards No. 30 -- Basic earnings per share.

As at 31 December 2025, the Company does not have shares with dilutive potential for earnings per share.

35. BUSINESS AND PRODUCTIONS COST BY ITEMS

	Year 2025	Year 2024
	VND	VND
Raw materials	9,835,818,132	9,786,159,930
Labour expenses	50,106,203,940	56,914,552,816
Depreciation expenses	10,952,459,975	4,098,032,090
Provision expenses	(1,199,049,501)	(780,084,856)
Expenses of outsourcing services	20,088,403,580	20,405,087,730
Other expenses in cash	18,726,389,787	12,193,500,256
	108,510,225,913	102,617,247,966

36. FINANCIAL INSTRUMENTS

Financial risk management

Financial risks that the Company may face risks including: market risk, credit risk and liquidity risk.

The Company has developed its control system to ensure the reasonable balance between cost of incurred risks and cost of risk management. The Board of Management of the Company is responsible for monitoring the risk management process to ensure the appropriate balance between risk and risk control.

Market risk

The Company may face with the market risk such as: changes in prices, exchange rates and interest rates.

Exchange rate risk:

The Company bears the risk of interest rates due to the transaction made in a foreign currency other than VND such as: borrowings and debts, revenue, cost, importing materials, goods, machinery and equipment....

Interest rate risk:

The Company bears the risk of interest rates due to the fluctuation in fair value of future cash flow of a financial instrument in line with changes in market interest rates if the Company has time or demand deposits, borrowings and debts subject to floating interest rates. The Company manages interest rate risk by analyzing the market competition situation to obtain interest beneficial for its operation purpose.

Credit Risk

Credit risk is the risk of financial loss to the Company if a counterparty fails to perform its contractual obligations. The Company has credit risk from operating activities (mainly to trade receivables) and financial activities (including deposits, loans and other financial instruments), detailed as follows:

	Under 1 year	From 1 to 5 years	Over 5 years	Total
As at 31/12/2025	VND	VND	VND	VND
Cash and cash equivalents	31,103,629,889	-	-	31,103,629,889
Trade and other receivables	604,516,418,828	-	-	604,516,418,828
Loans	145,759,600,000	-	-	145,759,600,000
	781,379,648,717	-	-	781,379,648,717

	Under 1 year VND	From 1 to 5 years VND	Over 5 years VND	Total VND
As at 01/01/2025				
Cash and cash equivalents	29,046,963,838	-	-	29,046,963,838
Trade and other receivables	664,902,623,839	-	-	664,902,623,839
Loans	177,644,270,909	-	-	177,644,270,909
	871,593,858,586	-	-	871,593,858,586

Liquidity Risk:

Liquidity risk is the risk that the Company has trouble in settlement of its financial obligations due to the lack of funds. Liquidity risk of the Company is mainly arises from different maturity of its financial assets and liabilities.

Due date for payment of financial liabilities based on expected payment under the contracts (based on cash flow of the original debts) as follows:

	Under 1 year VND	From 1 to 5 years VND	Over 5 years VND	Total VND
As at 31/12/2025				
Borrowings and debts	144,741,860,079	-	-	144,741,860,079
Trade and other payables	607,924,432,448	2,728,700,000	-	610,653,132,448
Accrued expenses	225,152,626	-	-	225,152,626
	752,891,445,153	2,728,700,000	-	755,620,145,153
As at 01/01/2025				
Borrowings and debts	160,107,128,634	-	-	160,107,128,634
Trade and other payables	738,910,778,762	2,481,600,000	-	741,392,378,762
Accrued expenses	92,978,488	-	-	92,978,488
	899,110,885,884	2,481,600,000	-	901,592,485,884

The Company believes that risk level of loan repayment is controllable. The Company has the ability to pay due debts from cash flows from its operating activities and cash received from mature financial assets.

37. ADDITIONAL INFORMATION FOR THE ITEMS OF THE SH FLOWS

a) Non-cash transactions affecting the statement of cash flow in the future

	Year 2025 VND	Year 2024 VND
a) Proceeds from borrowings during the year		
Proceeds from ordinary contracts;	955,221,755,065	884,954,644,376
b) Actual repayments on principal during the year		
Repayment on principal from ordinary contracts;	970,587,023,620	803,605,968,487

38. OTHER INFORMATION

Accounts receivable are guaranteed for payment by suppliers

As of December 31, 2025 and January 1, 2025, the Company's receivables from import-entrusted customers are guaranteed for payment by suppliers through Guarantee Agreements signed between three parties with the main terms including:

- Parties signing the agreement: Supplier, Danang Pharmaceutical and Medical Equipment Joint Stock Company and Customer;
- Guarantee period: Signed separately for each contract, effective until the Customer pays all receivables to the Company;
- Main content: The Company is not responsible for paying the supplier if the customer has not paid the Company. At the same time, if the customer is late in paying beyond the deadline (specified in each Guarantee Agreement), the Company is allowed to offset the customer's outstanding payment obligation against the supplier's outstanding debt.

Details of the balance of receivables from customers guaranteed under the Guarantee Agreements as at 31 December 2025 are presented in Note 5.

39. SUBSEQUENT EVENTS AFTER THE REPORTING PERIOD

There have been no significant events occurring after the reporting period, which would require adjustments or disclosures to be made in the Financial Statements.

40. TRANSACTION AND BALANCES WITH RELATED PARTIES

List and relation between related parties and Company are as follows:

Related parties	Relationship
Megram Joint Stock Company	Parent company
Danapha Pharmaceutical Joint Stock Company	Major
Elimich Joint Stock Company	Same group
The members of the Board of Directors, the Board of Management and the Board of Supervision	

In addition to the information with related parties presented in the above Notes, during the year the Company has transactions with related parties as follows:

	Year 2025	Year 2024
	VND	VND
Revenue from sales of goods and rendering of services	-	2,639,343
Danapha Pharmaceutical Joint Stock Company	-	2,639,343
Purchase	-	49,090,909
Elmich Joint Stock Company	-	49,090,909
Financial income	4,213,599,995	1,398,543,836
Elmich Joint Stock Company	4,213,599,995	1,398,543,836
General and Administration expenses	14,857,066	56,667,140
Megram Joint Stock Company	14,857,066	31,796,674
Elmich Joint Stock Company	-	24,870,466
Loan	126,000,000,000	91,900,000,000
Elmich Joint Stock Company	126,000,000,000	91,900,000,000
Loan recovery	152,200,000,000	37,800,000,000
Elmich Joint Stock Company	152,200,000,000	37,800,000,000

Transactions with the other related parties as follows:

	Position	Year 2025	Year 2024
Remuneration of the Board of Directors		VND	VND
- Do Thanh Trung	Chairman	33,000,000	100,000,000
- Nguyen Luong Tam	Chairman (Resigned on April 18, 2025)	27,000,000	100,000,000
	Member		
- Nguyen Trung	Member (Dismissal of Board of Directors members on December 1, 2025)	22,000,000	50,000,000
- Hoang Trung Dung	Member	24,000,000	100,000,000
- Vu Thien Tiep	Member (Appointment on December 1, 2025)	2,000,000	-
- Dinh Thi Mong Van	Member	24,000,000	70,000,000
- Pham Thi Minh Ngoc	Board Secretary	12,000,000	-
		144,000,000	420,000,000

	Position	Year 2025	Year 2024
Remuneration of the Board of Supervision		VND	VND
- Nguyen Thi Yen	Head of Board	18,000,000	20,000,000
- Pham Thi Minh Ngoc	Member	12,000,000	15,000,000
- Nguyen Thi Thanh Thuy	Member	12,000,000	15,000,000
		42,000,000	50,000,000

Salary, bonus and other benefits of the Board of Management and other managers

- Nguyen Luong Tam	General director (Appointment dated April 18, 2025)	2,072,817,453	-
	Member		
- Nguyen Trung	Deputy General director	913,305,063	615,362,471
- Nguyen Ba Hai	Deputy General director	1,213,268,752	129,964,939
- Tran Thi Anh Minh	Chief accountant	579,595,543	463,097,609
		4,778,986,811	1,208,425,019

In addition to the above related parties' transactions, other related parties did not have any transactions during the year and have no balance at the end of the fiscal year with the Company.

41. COMPARATIVE FIGURES

The comparative figures are figures in the Financial Statements for the fiscal year ended 31 December 2024, which were audited by AASC Auditing Firm Company Limited.

Da Nang, 25 March 2026

Preparer



Tran Khanh Linh

Chief Accountant



Tran Thi Anh Minh

Deputy General Director



Nguyen Trung